|
Aug 27
|
Cingulate to Participate in Benzinga All Live Access Event
|
|
Aug 26
|
CING: Initiating Coverage – Precision Timed Release Delivers Active-Day Coverage
|
|
Jun 25
|
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
|
|
Jun 25
|
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance
|
|
Feb 13
|
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
|
|
Feb 6
|
Cingulate Announces Closing of $7.5 Million Public Offering
|
|
Feb 2
|
Cingulate Announces Pricing of $7.5 Million Public Offering
|
|
Dec 5
|
Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now
|
|
Dec 1
|
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
|
|
Nov 13
|
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
|
|
Sep 11
|
Cingulate Announces Pricing of $4.0 Million Public Offering
|
|
Sep 8
|
Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium
|
|
Sep 5
|
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
|